Get the Stockscreener App
94.39
0.43%
0.40
After Hours:
94.70
0.31
+0.33%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $94.39, with a volume of 54.75M.
It is up +0.43% in the last 24 hours and up +3.33% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$93.99
Open:
$94.47
24h Volume:
54.75M
Relative Volume:
9.28
Market Cap:
$292.66B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
31.35
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
-0.27%
1M Performance:
+3.33%
6M Performance:
+34.69%
1Y Performance:
+41.07%
1-Day Range:
$93.51
$94.68
1-Week Range:
$92.78
$96.43
52-Week Range:
$61.24
$96.51
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
94.39 | 291.42B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
AstraZeneca (AZN) Acquires Modella AI to Boost Cancer Research - GuruFocus
AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development - Intellectia AI
JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN) - MarketBeat
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
What Makes AstraZeneca (AZN) a Strong Growing Company? - Insider Monkey
AstraZeneca Spotlights 2025 Growth, 2026 Launch Wave and $80B 2030 Goal at JPM Conference - Yahoo Finance
The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company) - The Motley Fool
Rep. Julia Letlow Buys AstraZeneca PLC (NASDAQ:AZN) Shares - MarketBeat
AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition - Pharmaceutical Technology
Manning & Napier Advisors LLC Sells 390,342 Shares of AstraZeneca PLC $AZN - MarketBeat
Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale - marketscreener.com
AstraZeneca (LON:AZN) Hits New 52-Week HighHere's Why - MarketBeat
Market Overview: Whats AstraZeneca PLC Depositary Receipts historical returnMarket Performance Recap & Intraday High Probability Alerts - baoquankhu1.vn
AstraZeneca: acquires Modella AI to strengthen its oncology research - marketscreener.com
AstraZeneca stock rating reiterated at Buy by Guggenheim ahead of Q4 results - Investing.com UK
AstraZeneca CFO on M&A Strategy and Obesity Market - marketscreener.com
AstraZeneca to acquire Modella AI to speed oncology drug research - Reuters
AstraZeneca (AZN) Awaits Conclusion of US Pharma Import Probe - GuruFocus
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
AstraZeneca (AZN) Broadens Oncology Efforts with Acquisition of ModellaAI - GuruFocus
AstraZeneca acquires AI firm to boost research - breakingthenews.net
Risks Report: What technical charts say about AstraZeneca PLC Depositary Receipt stockJuly 2025 Fed Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
Modella AI announces acquisition by AstraZeneca - marketscreener.com
AstraZeneca (AZN) Joins in Groundbreaking Genetic Research Initiative - GuruFocus
AstraZeneca (AZN) Progresses with Phase 3 TROPION-Lung17 Trial - GuruFocus
Walmart to join Nasdaq 100 on Jan. 20 as AstraZeneca exits - MSN
AstraZeneca (AZN) Set for Removal from Several Key Nasdaq Indexes - GuruFocus
SG Americas Securities LLC Grows Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to be replaced by Walmart in the Nasdaq-100 index — Check dates - The Financial Express
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $215.25 - 富途牛牛
Oliver Luxxe Assets LLC Buys 13,350 Shares of AstraZeneca PLC $AZN - MarketBeat
The Truth About AstraZeneca plc: Wall Street Sleeper Stock Or Overhyped Dinosaur? - AD HOC NEWS
The Truth About AstraZeneca plc: Is This Pharma Giant Still Worth Your Money? - AD HOC NEWS
Berenberg Bank Remains Bullish on AstraZeneca PLC (AZN) – Here’s Why - Insider Monkey
AstraZeneca stock set for Nasdaq-100 exit on Jan. 20 as Walmart takes its slot — what AZN investors watch next - TechStock²
Walmart to join Nasdaq 100 from January 20 as AstraZeneca exits the index - MSN
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Walmart to Join Nasdaq 100 Index on January 20 as AstraZeneca Exits - scanx.trade
AstraZeneca: Oncology Dominance Justifies New All-Time Highs (NASDAQ:AZN) - Seeking Alpha
Walmart Set to Enter Nasdaq 100 on January 20, Replacing AstraZeneca - Bitget
HB Wealth Management LLC Has $3.65 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
AstraZeneca - Britannica
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca - MSN
Walmart joins Nasdaq 100, $19 billion investment surge coming - Cryptopolitan
Walmart set to join Nasdaq 100 on January 20 as AstraZeneca drops out - Business Standard
Walmart to join Nasdaq 100 on Jan 20 as AstraZeneca exits - The Edge Malaysia
Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits - Bloomberg.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):